Loading stock data…
Karyopharm Therapeutics Inc (KPTI)
$10.09-0.13 (-1.22%)
Market ClosedLast close Jun 29
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Karyopharm Therapeutics Inc. in the Healthcare sector is trading at $10.09 with a market capitalization of $216M. Wall Street consensus targets $13.50 (6 analysts), implying a +33.9% move over the next 12 months. The stock is currently near its 52-week high of $10.99, remaining 36.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +33.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $35.07M↑ | $34.08M↓ | $44.04M↑ | $37.93M↑ | $30.02M |
| Gross Profit | $33.72M↑ | $32.59M↓ | $41.93M↑ | $36.88M↑ | $28.71M |
| Operating Income | -$26.76M↓ | -$17.84M↓ | -$15.22M↑ | -$24.39M↑ | -$33.26M |
| Net Income | -$22.39M↑ | -$102.20M↓ | -$33.13M↑ | -$37.25M↓ | -$23.46M |
Peer Comparison
JNJUNHPFE
Fundamentals
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develop...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$216.09M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
73.39%
Volume
Today's trading volume
490,480
Recent News
Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update
Price target moves around Karyopharm Therapeutics have been mixed, with some analysts lifting their targets by US$5 or US$8 while others cut theirs by US$7 or US$4. These shifts reflect differing reactions to recent data, guidance, and risk assessments. Bullish views tie higher targets to execution on the current pipeline, while more cautious views reset expectations around near term challenges. As you read on, you will see how to interpret this evolving narrative and what to watch next in...
How The Investment Story Is Evolving For Karyopharm Therapeutics (KPTI)
Karyopharm Therapeutics heads into this latest update with no changes to its current price targets, leaving existing analyst expectations in place for now. With no new commentary from covering analysts, investors are working from the same formal views that were already on the table. In the sections that follow, you will see how to track fresh research, interpret future target shifts, and keep up with the evolving narrative around this stock. Analyst Price Targets don't always capture the full...
Wall Street Analysts Think Karyopharm Therapeutics (KPTI) Could Surge 70.46%: Read This Before Placing a Bet
The consensus price target hints at a 70.5% upside potential for Karyopharm Therapeutics (KPTI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts
Karyopharm Therapeutics (NASDAQ:KPTI) executives used an H.C. Wainwright BioConnect Conference appearance to highlight upcoming clinical and regulatory milestones for selinexor, the company’s oral nuclear export inhibitor marketed as XPOVIO in multiple myeloma. Chief Executive Officer Richard Pauls
Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus
Karyopharm Therapeutics (NASDAQ:KPTI) executives said the company expects to provide a fuller presentation of its Phase 3 SENTRY trial data for selinexor in myelofibrosis at the upcoming ASCO conference, while also outlining expected regulatory engagement and other development priorities during a re